💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Lotus Eye Hospital and Institute Limited is an India-based company, which is engaged in the business of healthcare activities. The Company is engaged in the field of ophthalmology (eye) and its related operations. It resolves a range of eye problems, such as refractive,…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A weak, stagnant business, priced for perfection.
LOTUS EYE HOSPITAL is scored on the pharma / healthcare framework. It keeps a thin 0.1% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 37.75× reported profit. Free cash flow is worth about -4.2% of its market value.
Over the last 3 years revenue compounded at 4%/yr and profit at -73%/yr. Book value has been broadly flat (1.5%/yr). Return on equity is a weak 0.1%.
At 285× earnings, the stock sits at the 81st percentile of its own 3-year range — the expensive end of where it has historically traded. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 1525.71 | — | — |
| P/B | 3.69 | 3.5 | worse |
| EV/EBITDA | 39.15 | 19.83 | worse |
| ROE | 0.13 | — | — |
| ROCE | 1.06 | — | — |
| ROA | 0.18 | — | — |
| Quick Ratio | 0.81 | — | — |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Apollo Hospitals | 52.0 | 11.4 | 21.1% |
| Max Healthcare | 65.9 | 8.0 | 12.2% |
| Manipal Health Enterprises | 93.9 | 5.2 | 10.6% |
Revenue has grown every year across all 4 financial years shown. 4% CAGR — growing but slowly. Growth is accelerating — latest year outpaced the prior year's rate.
Revenue is outpacing profit (4% vs -73%) — costs are rising faster than the top line. The latest year saw a -89% swing — check if it's a one-off or structural.
Operating margin has compressed from 12% to -0% — costs or competition are eating into profitability. Interest or tax burden is shrinking — more of the operating profit is reaching the bottom line. Margins have declined for 3 consecutive years — watch for a structural cost problem.
ROE at 0% — modest; the capital isn't working hard. Capital efficiency declining — ROE down 7pp.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play. -73% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 37.8× PAT — earnings are well-backed by cash; strong accrual quality. Investing outflows exceed operating cash — the company relies on external funding to finance expansion.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 23% sequentially — momentum is building. Run-rate stepping up — recent quarters average 16% above earlier ones.
2 of 4 quarters loss-making — quarterly profitability is uneven. Profit jumped 291% QoQ — check if this is operating leverage or a one-off item. Quarterly net margins are expanding (1% → 4%) — profitability per rupee of revenue is improving.
How today's P/E compares to the stock's own historical range. Dashed line = the 3y median.
Promoters at 40.1% — dispersed ownership; institutional flows drive the stock.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.